Bicara Therapeutics (BCAX) Fundamental Analysis: Revenue, Earnings & Valuation

6.70 / 10

Outperform

Fundamental analysis rates BCAX as Outperform with a 6.7/10 score. Strengths include high inventory turnover, strong accounts receivable turnover, robust interest coverage, and favorable asset‑MV and revenue‑MV differentials. Weaknesses arise from low income‑tax‑to‑profit ratio and poor fixed‑asset turnover.

Analysis Checks(8/10)

Revenue-MV

Value-0.28

Score3/3

Weight29.91%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value78.05

Score2/3

Weight1.59%

1M Return0.58%

Inventory turnover ratio

Value47.57

Score3/3

Weight-1.70%

1M Return-0.67%

Accounts receivable turnover ratio

Value25.89

Score2/3

Weight-1.68%

1M Return-0.65%

PB-ROE

Value0.96

Score2/3

Weight33.54%

1M Return8.98%

Income tax / Total profit (%)

Value-0.16

Score1/3

Weight-1.54%

1M Return-0.59%

Fixed assets turnover ratio

Value7899.90

Score1/3

Weight-3.15%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-1.90%

1M Return-0.73%

Cost of sales ratio (%)

Value70.30

Score2/3

Weight-1.86%

1M Return-0.74%

Asset-MV

Value-0.48

Score3/3

Weight46.80%

1M Return13.09%

Is BCAX undervalued or overvalued?

BCAX scores 6.70/10 on fundamentals and holds a Discounted valuation at present. Backed by its -22.48% ROE, 0.00% net margin, -9.58 P/E ratio, 2.89 P/B ratio, and 117.52% earnings growth, these metrics solidify its Outperform investment rating.